The Latest Cardiac and Vascular News
AACHEN, Germany–(BUSINESS WIRE)–Protembis GmbH, a privately held medical device company, announced today the first clinical applications of its ProtEmbo® Cerebral Protection System to complement a transcatheter aortic valve replacement (TAVR) procedure. The ProtEmbo® System is an intra-aortic filter device that deflects embolic material arising during TAVR away from the brain. Darren Mylotte, […]
REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that Anthem Blue Cross Blue Shield, Blue Shield of California, and Blue Cross and Blue Shield of Alabama have each issued a positive medical policy for the HeartFlow® FFRct Analysis, a first-of-its-kind noninvasive technology that helps clinicians diagnose and treat patients with suspected coronary artery […]
ABBOTT PARK, Ill., Aug. 30, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified version of its AMPLATZER™ device designed to correct a common congenital heart defect that occurs in approximately 80,000 i,ii pre-term infants in the U.S. each year. […]
Landmark Data Published by The Lancet Demonstrates Statistically Significant Lower Event Rates with Orsiro BARCELONA, Spain, August 28, 2017 – BIOTRONIK today announced data from the BIOFLOW-V randomized trial comparing Orsiro1 and Xience2 drug-eluting stents (DES) with 12-month target lesion failure (TLF) as the primary endpoint proving non-inferiority. Results presented at the […]
Global collaboration aims to accelerate access to tools to determine extent of coronary artery disease and improve patient care Amsterdam, the Netherlands and Redwood City, Calif. – Royal Philips (NYSE: PHG, AEX: PHIA) and HeartFlow, Inc. announced today that they have entered into a collaboration agreement with the goal of […]
RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® dual therapy was used instead of warfarin triple therapy. Both Pradaxa® doses tested in RE-DUAL PCI™ have been approved for stroke prevention in atrial fibrillation. Data were presented as a late-breaker at the ESC Congress 20171 and published in the […]
Bleeding rates were low, and while major bleeding was increased, notably, there was no significant increase in intracranial or fatal bleeding1. This combination regimen demonstrated a substantial improvement in net clinical benefit of 20%1. Data from Canadian-led COMPASS study, revealed at ESC Congress 2017, included 27,395 patients globally and […]
PASADENA, Calif., Aug. 24, 2017 /PRNewswire/ — Men with localized prostate cancer who received androgen deprivation therapy, a hormone treatment, were at significantly higher risk of heart failure than men who did not receive this therapy, according to a Kaiser Permanente study published today in the British Journal of Cancer. In the past, […]
TEL AVIV, ISRAEL–(Marketwired – August 22, 2017) – InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has posted video testimonials about its CGuard™ Embolic Prevention System from […]
SAN RAMON, Calif. and CAMBRIDGE, England, Aug. 21, 2017 /PRNewswire/ — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced enrollment of the first patient in the international arm of the ALIVE pivotal clinical trial. The trial is designed to demonstrate the safety and effectiveness of […]
